Physician profile
John C Feore
NPI 1861472896
$771.33
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $110 · 2021: $284 · 2022: $55.94 · 2023: $44.27 · 2024: $14.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169.18 | 2021-2023 | |
| Lupin INC. | $90.55 | 2019 | |
| Merck Sharp & Dohme LLC | $68.88 | 2019-2021 | |
| Pfizer INC. | $59.29 | 2019-2023 | |
| Astellas Pharma US INC | $54.31 | 2019-2023 | Veozah |
| Myovant Sciences INC. | $35.97 | 2021-2022 | |
| Coopersurgical, INC. | $33.20 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $32.17 | 2019 | |
| Therapeuticsmd, INC. | $27.21 | 2019-2020 | |
| Exeltis, USA INC. | $25.94 | 2020-2021 | |
| Agile Therapeutics, INC. | $25.40 | 2021 | |
| Mayne Pharma Commercial LLC | $23.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.38 | 2021 | |
| Allergan, INC. | $18.22 | 2019 | |
| Daiichi Sankyo INC. | $17.64 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $15.62 | 2019 | |
| Biogen, INC. | $14.71 | 2024 | |
| Smith+Nephew, INC. | $14.03 | 2019 | |
| Evofem Biosciences, INC. | $13.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Feore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.